Qiagen (NYSE:QGEN) Releases Q1 2025 Earnings Guidance

Qiagen (NYSE:QGEN) updated its first quarter 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.500- for the period, compared to the consensus EPS estimate of 0.500. The company issued revenue guidance of $472.8 million-, compared to the consensus revenue estimate of $477.5 million. Qiagen also updated its FY 2025 guidance to 2.280- EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on QGEN shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.50 price target (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $46.67 target price (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective for the company. in a report on Thursday, October 17th. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $50.07.

Qiagen Price Performance

NYSE QGEN traded down $1.71 during trading hours on Thursday, reaching $42.09. The company’s stock had a trading volume of 684,259 shares, compared to its average volume of 1,139,865. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of 104.85, a P/E/G ratio of 3.10 and a beta of 0.36. The company’s 50-day moving average is $43.80 and its two-hundred day moving average is $43.26. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. Qiagen has a 1-year low of $40.15 and a 1-year high of $49.30.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. On average, equities analysts predict that Qiagen will post 2.23 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.